Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$316.17 USD

316.17
199,913

-1.85 (-0.58%)

Updated Jul 23, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Rimmi Singhi headshot

COVID-19 Vaccine Rollout Challenges Put These Stocks in Focus

With COVID-19 vaccine on the horizon, cold-chain storage stocks including TT, CARR and TMO; vial makers like GLW and WST; and logistic operators including UPS and FDX are set to hog the limelight.

Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat

Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.

Has West Pharmaceutical Services (WST) Outpaced Other Medical Stocks This Year?

Is (WST) Outperforming Other Medical Stocks This Year?

Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat

Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.

Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y

In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.

Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

National Vision (EYE) Q3 Earnings Top Estimates, Margins Up

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.

Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up

CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up

Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.

Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%

Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise

Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates

Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.

Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates

Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.

Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat

Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2

STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.

Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y

Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.

Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline

Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.

NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines

NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Rise

ResMed's (RMD) overall increase in Q1 revenues is driven by robust performance of its mask and device product portfolios on increased demand for ventilators and ventilator masks.

Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q3 earnings.